Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of "Scratch Resistance," its new ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 ...

Many people experience an itchy scalp at some point. It’s usually not a sign of a serious medical condition and can, in most ...

For millions of people around the world, asthma is more than just a breathing problem—it is a chronic and often debilitating ...

Patients with suspected eyelid allergic contact dermatitis can benefit from patch testing beyond common allergens.

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Tralokinumab use in patients with head and neck atopic dermatitis was associated with sustained improvements with up to 4 years of treatment.

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...